Aytu BioPharma to Present at Upcoming October 2025 Conferences
Aytu BioPharma (NASDAQ:AYTU) announced that management will participate in two investor conferences in October 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma (NASDAQ:AYTU) announced that management will participate in two investor conferences in October 2025.
Events: Maxim Growth Summit on October 22, 2025 in New York City, and Planet MicroCap Showcase: TORONTO 2025 on October 22–23, 2025 in Toronto. The Planet MicroCap presentation is scheduled for 2:30 p.m. ET and will be available via webcast.
Investor access: Investors may schedule one-on-one meetings by contacting their Maxim sales representative or Robert Blum of Lytham Partners at aytu@lythampartners.com. Registration is required to attend the Planet MicroCap Showcase and the webcast link is provided for remote viewing.
Details
News Market Reaction – AYTU
On Oct 10, the day this news came out, AYTU closed 5.98% below the previous close.
Data tracked by StockTitan Argus for the Oct 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
2025 Maxim Growth Summit
Date: October 22, 2025
Location: New York City
Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at aytu@lythampartners.com to schedule one-on-one meetings with Aytu's management.
Planet MicroCap Showcase: TORONTO 2025
Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja
If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at aytu@lythampartners.com to assist in coordination.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.